# Abraxane in Treatment of Metastatic Breast Cancer

> **NCT02555696** · — · COMPLETED · sponsor: **Celgene** · enrollment: 203 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT02555696
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-31
- **Primary completion:** 2016-02-28
- **Final completion:** 2016-12-31
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555696, "Abraxane in Treatment of Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02555696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*